Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Allogene Therapeutics To Present Pre-Clinical Data Highlighting Potential Of ALLO-329 At ACR Convergence
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
Allogene Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target
H.C. Wainwright Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright analyst Robert Burns maintains $Allogene Therapeutics(ALLO.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 24
CCORF Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $14
CCORF analyst John Newman maintains $Allogene Therapeutics(ALLO.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 37.6% and
Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript
Citigroup Maintains Buy on Allogene Therapeutics, Raises Price Target to $8
Allogene Therapeutics Analyst Ratings
Express News | Allogene Therapeutics Inc : Truist Securities Cuts Target Price to $14 From $17
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Express News | Allogene Therapeutics Inc : Citigroup Raises Target Price to $8 From $7
Allogene Therapeutics Coverage Assumed by Oppenheimer at Outperform
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
Truist Adjusts Allogene Therapeutics' PT to $14 From $17, Keeps Buy Rating
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Express News | Allogene : Oppenheimer Cuts Target Price to $11 From $13